- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Opinion
Video
Expert Perspectives on BOLT clinical trial data
John Strasswimmer, MD, PhD comments on the impressive utility of both vismodegib and sonidegib in patients with advanced basal cell carcinoma and Jonathan S Zager, MD, FACS, FSSO provides his insight into the clinical utility of both of these treatments.
Jonathan S Zager, MD, FACS, FSSO
Moffitt Cancer Center
Tampa, Florida
Lilia Correa-Selm, MD, FAAD, FACMS
Moffitt Cancer Center
Tampa, Florida
Aaron Farberg, MD
Bare Dermatology
Dallas, Texas
John Strasswimmer, MD, PhD
Florida Atlantic University
Delray Beach, Florida
Andrew Weinstein, MD, MPH, FAAD
Boynton Beach Skin, University of Miami
Boynton Beach and Coral Gables, Florida
Series Description: Experts in dermatology discuss the clinical trial data from the BOLT and EVRIANCE clinical trials and review patient cases related to the management of patients with locally advanced basal cell carcinoma treated with sonidegib and vismodegib.
Segment Description: John Strasswimmer, MD, PhD comments on the impressive utility of both vismodegib and sonidegib in patients with advanced basal cell carcinoma and Jonathan S Zager, MD, FACS, FSSO provides his insight into the clinical utility of both of these treatments.
